AGENUS INC (AGEN) Spending and interest coverage
- R&D / revenue · 12 months: Value 43.47%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.60%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 43.47% | Research and development expense / revenue. Period ending 2026-06-30. $57.69M ÷ $132.69M × 100 ≈ 43.47% |
| Stock-based compensation / revenue · 12 months | 8.60% | Share-based compensation / revenue. Period ending 2026-06-30. $11.41M ÷ $132.69M × 100 ≈ 8.60% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 57.69M USD | Research and Development Expense |
| Revenue | 132.69M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 11.41M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 36.20M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $57.69M | $132.69M | $11.41M | $36.20M | (m) | 43.47% | 8.60% | (m) | (m) |
| 2026-03-31 | $69.64M | $123.87M | $11.39M | $8.20M | (m) | 56.22% | 9.19% | (m) | (m) |
| 2025-12-31 | $79.34M | $114.20M | $13.77M | $-20.17M | (m) | 69.48% | 12.06% | (m) | (m) |
| 2025-09-30 | $105.60M | $106.83M | $14.98M | $-60.46M | (m) | 98.85% | 14.03% | (m) | (m) |
| 2025-06-30 | $123.06M | $101.71M | $16.27M | $-87.42M | (m) | 121.00% | 16.00% | (m) | (m) |
| 2025-03-31 | $133.13M | $99.52M | $16.72M | $-100.90M | (m) | 133.76% | 16.80% | (m) | (m) |
| 2024-12-31 | $155.53M | $103.46M | $17.39M | $-120.47M | (m) | 150.32% | 16.81% | (m) | (m) |
| 2024-09-30 | $188.48M | $160.43M | $18.18M | $-98.78M | (m) | 117.48% | 11.33% | (m) | (m) |
| 2024-06-30 | $198.86M | $159.63M | $19.53M | $-113.62M | (m) | 124.58% | 12.23% | (m) | (m) |
| 2024-03-31 | $221.38M | $161.42M | $21.54M | $-138.09M | (m) | 137.15% | 13.34% | (m) | (m) |
| 2023-12-31 | $234.57M | $156.31M | $22.87M | $-159.55M | (m) | 150.06% | 14.63% | (m) | (m) |
| 2023-09-30 | $221.13M | $100.90M | $21.67M | $-213.10M | (m) | 219.15% | 21.47% | (m) | (m) |
| 2023-06-30 | $215.69M | $99.36M | $20.24M | $-208.41M | (m) | 217.09% | 20.37% | (m) | (m) |
| 2023-03-31 | $201.37M | $94.98M | $18.83M | $-198.31M | (m) | 212.00% | 19.83% | (m) | (m) |
| 2022-12-31 | $186.69M | $98.02M | $18.34M | $-179.43M | (m) | 190.45% | 18.71% | (m) | (m) |
| 2022-09-30 | $186.90M | $89.90M | $19.28M | $-175.70M | (m) | 207.90% | 21.44% | (m) | (m) |
| 2022-06-30 | $183.83M | $320.08M | $19.61M | $53.49M | (m) | 57.43% | 6.13% | (m) | (m) |
| 2022-03-31 | $184.37M | $309.89M | $20.57M | $31.66M | (m) | 59.50% | 6.64% | (m) | (m) |
| 2021-12-31 | $178.61M | $295.67M | $19.58M | $25.75M | (m) | 60.41% | 6.62% | (m) | (m) |
| 2021-09-30 | $160.69M | $306.67M | $17.12M | $58.07M | (m) | 52.40% | 5.58% | (m) | (m) |
| 2021-06-30 | $149.89M | $68.55M | $15.06M | $-164.26M | (m) | 218.67% | 21.96% | (m) | (m) |
| 2021-03-31 | $142.93M | $84.76M | $12.02M | $-131.14M | (m) | 168.63% | 14.18% | (m) | (m) |
| 2020-12-31 | $142.62M | $88.17M | $10.42M | $-117.23M | (m) | 161.75% | 11.81% | (m) | (m) |
| 2020-09-30 | $143.88M | $91.41M | $10.72M | $-114.80M | (m) | 157.41% | 11.73% | (m) | (m) |
| 2020-06-30 | $157.88M | $96.51M | $11.08M | $-115.94M | (m) | 163.58% | 11.48% | (m) | (m) |
| 2020-03-31 | $164.57M | $85.28M | $10.45M | $-123.81M | (m) | 192.97% | 12.25% | (m) | (m) |
| 2019-12-31 | $168.34M | $150.05M | $9.89M | $-70.14M | (m) | 112.19% | 6.59% | (m) | (m) |
| 2019-09-30 | $167.54M | $122.00M | $8.77M | $-90.29M | (m) | 137.33% | 7.19% | (m) | (m) |
| 2019-06-30 | $151.26M | $114.86M | $7.60M | $-80.44M | (m) | 131.69% | 6.61% | (m) | (m) |
| 2019-03-31 | $135.29M | $115.04M | $7.26M | $-55.86M | (m) | 117.60% | 6.31% | (m) | (m) |
| 2018-12-31 | $124.60M | $36.78M | $7.63M | $-123.82M | (m) | 338.74% | 20.73% | (m) | (m) |
| 2018-09-30 | $120.44M | $38.69M | $11.04M | $-114.39M | (m) | 311.32% | 28.54% | (m) | (m) |
| 2018-06-30 | $116.38M | $29.24M | $11.09M | $-119.98M | (m) | 397.94% | 37.92% | (m) | (m) |
| 2018-03-31 | $112.93M | $17.56M | $12.26M | $-132.29M | (m) | 643.19% | 69.81% | (m) | (m) |
| 2017-12-31 | $116.13M | $42.88M | $12.43M | $-103.80M | (m) | 270.83% | 28.99% | (m) | (m) |
| 2017-09-30 | $110.24M | $40.10M | $11.57M | $-93.49M | (m) | 274.91% | 28.86% | (m) | (m) |
| 2017-06-30 | $106.04M | $41.19M | $12.00M | $-98.05M | (m) | 257.46% | 29.14% | (m) | (m) |
| 2017-03-31 | $102.57M | $43.57M | $10.80M | $-92.77M | (m) | 235.42% | 24.79% | (m) | (m) |
| 2016-12-31 | $94.97M | $22.57M | $13.19M | $-107.48M | (m) | 420.72% | 58.42% | (m) | (m) |
| 2016-09-30 | $86.94M | $24.64M | $10.92M | $-105.95M | (m) | 352.88% | 44.33% | (m) | (m) |
| 2016-06-30 | $83.85M | $27.04M | $9.31M | $-80.79M | (m) | 310.12% | 34.43% | (m) | (m) |
| 2016-03-31 | $86.26M | $26.82M | $10.71M | $-90.38M | (m) | 321.60% | 39.92% | (m) | (m) |
| 2015-12-31 | $70.44M | $24.82M | $7.44M | $-80.70M | (m) | 283.85% | 29.97% | (m) | (m) |
| 2015-09-30 | $59.86M | $18.80M | $6.19M | $-79.88M | (m) | 318.48% | 32.93% | (m) | (m) |
| 2015-06-30 | $46.65M | $13.51M | $6.70M | $-76.48M | $1.57M | 345.22% | 49.55% | -48.65× | Reported |
| 2015-03-31 | $27.10M | $10.21M | $5.21M | $-51.79M | $1.30M | 265.40% | 51.04% | -39.76× | Reported |
| 2014-12-31 | $22.35M | $6.98M | $4.67M | $-43.32M | $1.26M | 320.31% | 66.96% | -34.34× | Reported |
| 2014-09-30 | $18.22M | $5.75M | $4.54M | $-32.22M | $1.32M | 316.84% | 78.87% | -24.35× | Reported |
| 2014-06-30 | $16.83M | $4.92M | $4.02M | $-31.37M | $1.36M | 341.82% | 81.73% | -23.06× | Reported |
| 2014-03-31 | $14.92M | $2.66M | $4.37M | $-30.20M | $1.55M | 561.72% | 164.57% | -19.42× | Reported |
| 2013-12-31 | $13.01M | $3.05M | $4.13M | $-24.98M | $2.43M | 427.08% | 135.55% | -10.29× | Reported |
| 2013-09-30 | $8.99M | $3.74M | $4.02M | $-22.98M | $6.13M | 240.31% | 107.29% | -3.75× | Reported |
| 2013-06-30 | $10.28M | $3.88M | $4.06M | $-20.71M | $5.29M | 265.28% | 104.79% | -3.91× | Reported |
| 2013-03-31 | $10.69M | $3.70M | $4.11M | $-19.15M | $4.63M | 289.22% | 111.11% | -4.14× | Reported |
| 2012-12-31 | $10.56M | $15.96M | $4.30M | $-6.74M | $4.72M | 66.19% | 26.97% | -1.43× | Reported |
| 2012-09-30 | $11.05M | $15.51M | $4.58M | $-7.43M | $4.60M | 71.22% | 29.52% | -1.61× | Reported |
| 2012-06-30 | $10.97M | $15.30M | $4.21M | $-7.33M | $4.51M | 71.71% | 27.52% | -1.63× | Reported |
| 2012-03-31 | $10.88M | $15.46M | $2.91M | $-6.26M | $4.40M | 70.41% | 18.84% | -1.42× | Reported |
| 2011-12-31 | $11.02M | $2.76M | $2.65M | $-19.09M | $4.21M | 399.97% | 96.04% | -4.53× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $12.88M | $3.36M | $3.15M | $-21.75M | $4.87M | 383.31% | 93.81% | -4.47× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $16.90M | $3.33M | $3.13M | $-27.68M | $5.34M | 506.91% | 93.89% | -5.18× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |